Thus, targeting ERK and JNK MAPKs might provide a therapeutic option for containing the release of the pro-inflammatory cytokines from FLS, and could help to protect the elevated bone resorption, as observed during inflammatory conditions such as rheumatoid arthritis and periprosthetic osteolysis. The gene discussed is MAPK8; the disease is rheumatoid arthritis.